AlphaQuest LLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 177.1% in the fourth quarter, ...

Investment analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Denali Therapeutics in a ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) ...

On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug. Denali Therapeutics showcases ...

In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Buy recommendation. As of January 29, 2025, the average one-year price ...

In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other companies Bezos is investing in. Since leaving his position as CEO of Amazon ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...